Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Shares Outstanding (Weighted Average) (2021 - 2025)

Prime Medicine's Shares Outstanding (Weighted Average) history spans 5 years, with the latest figure at $148.8 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 25.43% year-over-year to $148.8 million; the TTM value through Dec 2025 reached $148.8 million, up 25.43%, while the annual FY2025 figure was $148.8 million, 25.43% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $148.8 million in Q4 2025 per PRME's latest filing, down from $160.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $160.5 million in Q3 2025 to a low of $11.8 million in Q3 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $83.3 million, with a median of $90.7 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): skyrocketed 367.52% in 2023, then grew 15.52% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $13.0 million in 2021, then soared by 161.23% to $33.9 million in 2022, then surged by 168.42% to $91.0 million in 2023, then skyrocketed by 30.37% to $118.6 million in 2024, then rose by 25.43% to $148.8 million in 2025.
  • Per Business Quant, the three most recent readings for PRME's Shares Outstanding (Weighted Average) are $148.8 million (Q4 2025), $160.5 million (Q3 2025), and $129.2 million (Q2 2025).